正在继续阐明的癌基因概念已进入临床试验。研究人员试图用新的和常规的化疗制剂对抗病人的瘤细胞,利用组织培养测出癌基因的作用。这些培养试验类似试管内的抗生素敏感试验。换句话说,当认识到肿瘤中哪些基因被激活后,科学家就可施用一种方法,使治疗针对引起肿瘤增生的特异而原发的代谢途径。迄今,他们用以下两种制剂获得一部分成效,即光辉霉素和干扰素。伯明翰阿拉巴马大学的研究组采用光辉霉素治疗已获得成功,密西根大学的研 The ongoing concept of oncogenes has entered clinical trials. Researchers tried to use new and conventional chemotherapeutic agents to fight tumor cells in patients and use tissue culture to measure the effects of oncogenes. These culture tests resemble in vitro antibiotic susceptibility tests. In other words, when one recognizes which genes in the tumor have been activated, scientists can apply a method that allows the treatment to target the specific and primary metabolic pathway that causes tumor growth. To date, they have achieved some of the results with two formulations, namely mithramycin and interferon. Research group at the University of Alabama in Birmingham has been successfully treated with lightomycin, and the University of Michigan studied